Patents by Inventor Ignacio Moraga Gonzalez

Ignacio Moraga Gonzalez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES
    Publication number: 20230372483
    Abstract: Chimeric antigen receptor molecules that include a variant IL-13. The variant IL-13 are more selective for IL13R?2 than IL13R?1 by virtue of weaker binding to IL13R?1. The chimeric antigen receptors can be used to treat IL13R?2 expressing cancers.
    Type: Application
    Filed: January 19, 2021
    Publication date: November 23, 2023
    Inventors: Christine E. Brown, Lawrence Stern, Xin Yang, K. Christopher Garcia, Ignacio Moraga Gonzalez
  • IL-10 MUTEINS
    Publication number: 20230203117
    Abstract: The present disclosure relates to modified forms, or muteins, of IL-10, as well as variants thereof, which display improved features as compared to wild-type IL-10. The present invention further relates to the use of such modified forms, or muteins, of IL-10, as well as variants thereof in methods, including therapeutic methods.
    Type: Application
    Filed: March 10, 2021
    Publication date: June 29, 2023
    Inventors: Claire Gorby, Ignacio Moraga Gonzalez, Suman Mitra
  • THERAPEUTIC IL-13 POLYPEPTIDES
    Publication number: 20210375184
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Application
    Filed: July 29, 2021
    Publication date: December 2, 2021
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • SYNTHEKINE COMPOSITIONS AND METHODS OF USE
    Publication number: 20210260162
    Abstract: Engineered synthekines and methods of use thereof are provided.
    Type: Application
    Filed: March 7, 2018
    Publication date: August 26, 2021
    Inventors: Ignacio Moraga Gonzalez, Kenan Christopher Garcia
  • Therapeutic IL-13 polypeptides
    Patent number: 11084858
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 10, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University Stanford, CA
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • IL-13/IL-4 SUPERKINES: IMMUNE CELL TARGETING CONSTRUCTS AND METHODS OF USE THEREOF
    Publication number: 20210214410
    Abstract: Methods and compositions are provided for enhancing anti-tumor effector immune cells with a targeting construct comprising a human IL-13 superkine and/or a human IL-4 superkine. Cytokine or additional co-stimulatory sequences may also be included to enhance the tumoricidal effects of the cells.
    Type: Application
    Filed: June 3, 2019
    Publication date: July 15, 2021
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez, Fahar Merchant
  • IL-13 SUPERKINE: IMMUNE CELL TARGETING CONSTRUCTS AND METHODS OF USE THEREOF
    Publication number: 20200095301
    Abstract: Methods and compositions are provided for enhancing anti-tumor effector immune cells with a targeting construct a human IL-13 superkine. Cytokine or additional co-stimulatory sequences may also be included to enhance the tumoricidal effects of the cells.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 26, 2020
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez, Fahar Merchant
  • THERAPEUTIC IL-13 POLYPEPTIDES
    Publication number: 20190144518
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 16, 2019
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • Therapeutic IL-13 polypeptides
    Patent number: 10227389
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: March 12, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • THERAPEUTIC IL-13 POLYPEPTIDES
    Publication number: 20170246251
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Application
    Filed: May 17, 2017
    Publication date: August 31, 2017
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • Therapeutic IL-13 polypeptides
    Patent number: 9732133
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 15, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • Therapeutic IL-13 Polypeptides
    Publication number: 20170066809
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 9, 2017
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • Modified IL-13 polypeptides
    Patent number: 9512194
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 6, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez
  • Therapeutic IL-13 Polypeptides
    Publication number: 20150056162
    Abstract: Variant IL-13 polypeptides are provided, which are engineered to have one or more of the following properties: (a) altered affinity for IL-13R?2, relative to the native human IL-13 protein; (b) altered affinity for IL-13R?1 relative to the native human IL-13 protein; (c) a disruption in the binding site for IL-4R? relative to the native human IL-13 protein.
    Type: Application
    Filed: January 25, 2013
    Publication date: February 26, 2015
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kenan Christopher Garcia, Ignacio Moraga Gonzalez